Skip to main content

and
  1. No Access

    Article

    RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Although clinical trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the exp...

    Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, **angju Kong in Nature (2011)

  2. Article

    Open Access

    CRAF R391W is a melanoma driver oncogene

    Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known. We es...

    Mohammad Atefi, Bjoern Titz, Jennifer Tsoi, Earl Avramis, Allison Le in Scientific Reports (2016)

  3. Article

    Open Access

    Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors

    BRAF inhibitors are highly effective therapies for the treatment of BRAFV600-mutated melanoma, with the main toxicity being a variety of hyperproliferative skin conditions due to paradoxical activation of the mit...

    Helena Escuin-Ordinas, Shuoran Li, Michael W. **e, Lu Sun in Nature Communications (2016)